We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Visby Medical

Visby Medical is transforming the order of diagnosis and treatment for infectious diseases so clinicians can test, ta... read more Featured Products: More products

Download Mobile App




POC STI Test Shortens Time from ED Arrival to Test Results

By LabMedica International staff writers
Posted on 04 Jun 2024
Print article
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics to treat these STIs. This misuse has contributed to the development of antimicrobial-resistant strains of Neisseria gonorrhoeae (NG), prompting WHO to issue new guidelines for diagnosing STIs, including the use of point-of-care (POC) tests, focusing particularly on reducing antimicrobial resistance. The increasing STI rates have posed a significant challenge to hospital emergency departments, as traditional tests do not yield results quickly enough to guide treatment decisions during a patient's visit. Consequently, clinicians often must decide on treatment before obtaining definitive results, exacerbating the issue of antibiotic resistance.

Now, a new study has demonstrated that a POC polymerase chain reaction (PCR) test can reduce the time from specimen collection to STI result to just 47 minutes per patient, compared to the 25-hour average with the standard of care (SOC) lab-processed molecular send-out tests. This test also led to significantly higher rates of appropriate treatment and lower rates of antibiotic over-treatment for Chlamydia trachomatis (CT) and NG infections, relative to SOC. Conducted by Visby Medical (San Jose, CA, USA) and John Hopkins University (Baltimore, MD, USA), the study assessed a new approach to managing the three most common non-viral STIs in women, comparing two testing methods at the Johns Hopkins Emergency Department over two separate four-month study periods in 2022 and 2023.

The two methods included SOC central laboratory testing with batched nucleic acid amplification testing (NAAT) and the POC PCR Visby Medical Sexual Health Test. They were evaluated for STI detection rates, median time-to-result intervals, and rates of appropriate treatment according to CDC guidelines. The Visby Medical Sexual Health Test, an "instrument-free" POC test that delivers PCR results in under 30 minutes, is the only one of its kind available in the U.S. In March 2023, this test received 510(k) clearance and a CLIA waiver from the U.S. Food and Drug Administration for its second-generation POC test. The study found that appropriate treatment proportions were significantly higher in the POC group. Additionally, the median time intervals for the POC group were significantly shorter, including the time from specimen collection to STI results, the time from patient arrival in the emergency department to STI results, and the time from ED arrival to patient discharge.

“The dramatic improvements seen with the Visby Sexual Health test in testing time, ED visit duration, and in the use of antibiotics point the way toward a new best practice for STI testing,” said Gary Schoolnik, MD, an infectious disease expert, Chief Medical Officer at Visby Medical, and Professor of Medicine at Stanford University. “Implementation of a new rapid point-of-care testing standard of care would greatly benefit our hospitals, urgent care centers and, most importantly, women who seek treatment for this condition.”

Related Links:
Visby Medical
John Hopkins University

New
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Gold Member
Veterinary Hematology Analyzer
Exigo H400
New
DVT/PE Test
VIDAS D-DIMER EXCLUSION II
New
Blood Gas Panel plus Electrolytes
i-STAT EG6+ Cartridge

Print article

Channels

Molecular Diagnostics

view channel
Image: RT-QuIC Prion, CSF is the only definitive antemortem clinical test of its kind that doesn’t involve a brain biopsy (Photo courtesy of Mayo Clinic)

CSF Test Distinguishes Prion Disease from Other Causes of Rapidly Progressive Dementia

Rapidly progressive dementias are a category of dementia where patients experience a swift decline from the onset of symptoms to losing functional independence, typically within two years.... Read more

Immunology

view channel
Image: New insights into preterm infant immunity could inform care (Photo courtesy of 123RF)

New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood

Preterm infants are particularly vulnerable due to their organs still undergoing development, which can lead to difficulties in breathing, eating, and regulating body temperature. This is especially true... Read more

Pathology

view channel
Image: The Results Manager System (Photo courtesy of QuidelOrtho)

Informatics Solution Elevates Laboratory Efficiency and Patient Care

QuidelOrtho Corporation (San Diego, CA, USA) has introduced the QuidelOrtho Results Manager System, a cutting-edge informatics solution designed to meet the increasing demands of modern laboratories.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.